This webinar discusses how relapses of ALL in children after initial remission and refractoriness to current chemotherapy agents remains a challenge for a small group of children, the new therapies necessary to achieve cure, and strategies for treatment.
Professor Hiroto Inaba will be discussing the optimal use of Immunotherapy agents in high risk ALL and how we can reduce the relapse risk in such children.
Professor Vaskar Saha will discuss the strategies of treating relapsed refractory ALL highlighting the lessons learnt from R3 and IntReALL trials. He will also discuss how these strategies can be adapted in developing world to improve outcome in children who currently have poor prognosis without very advanced treatment facilities.
Prof Hiroto Inaba
Member, Leukemia/Lymphoma Division, Department of Oncology
St. Jude Children’s Research Hospital
Memphis, Tennessee, USA
Prof Vaskar Saha
Professor of Paediatric Oncology, University of Manchester
Head, Paediatric Haematology and Oncology, Tata Medical Center, Kolkata
Director Tata Translational Cancer Research Centre, Kolkata
DBT-Wellcome Margdarshi Fellow
Paediatric Haematology Oncology BMT
KK Women’s and Children’s Hospital
This webinar is sponsored with an educational grant from Amgen.
Participants are invited to connect with AMGEN via: bit.ly/Webinar_AMGEN_Consent
This educational material is intended to provide information on research activities and may refer to products not approved for use in Singapore and/or unapproved uses of products approved in Singapore.
The views expressed in this presentation are those of the presenter.
Amgen Singapore does not endorse the promotion of unapproved products or indications.